Quiz Ref ID Brainstem metastases (BSM) represent 4% to 7% of all secondary intracranial tumors
1-4 but are not amenable to resection owing to a high risk of morbidity or mortality from damage to critical neurologic structures. Stereotactic radiosurgery (SRS) is an effective treatment for nonbrainstem brain metastases (BM) that does not cause the neurocognitive deficits of whole-brain radiotherapy (WBRT).
5 Nearly all prospective trials of SRS for BM have excluded patients with BSM.
5-10 Thus, reports of SRS for BSM are limited to small retrospective series,
11-43 and the efficacy and safety of SRS for BSM are incompletely understood. To address this unmet need, we performed a quantitative meta-analysis of SRS for BSM to estimate pooled measures of efficacy and safety in the context of prospective trials of SRS or molecular therapy for nonbrainstem BM.